Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.
about
Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreasThe development, past achievements, and future directions of brain PETQuantitative Impact of Plasma Clearance and Down-regulation on GLP-1 Receptor Molecular Imaging.Manganese-enhanced magnetic resonance imaging detects declining pancreatic β-cell mass in a cyclophosphamide-accelerated mouse model of type 1 diabetes.Noninvasive assessment of pancreatic beta-cell function in vivo with manganese-enhanced magnetic resonance imaging.Quantitative pancreatic β cell MRI using manganese-enhanced Look-Locker imaging and two-site water exchange analysis.Characterization of 5-(2- 18F-fluoroethoxy)-L-tryptophan for PET imaging of the pancreas.Generation of novel single-chain antibodies by phage-display technology to direct imaging agents highly selective to pancreatic beta- or alpha-cells in vivo.Imaging pancreas in healthy and diabetic rodent model using [18F]fallypride positron emission tomography/computed tomography.Arginine is preferred to glucagon for stimulation testing of β-cell function.New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2)Noninvasive imaging of islet grafts using positron-emission tomography.Genome-wide DNA methylation analysis of human pancreatic islets from type 2 diabetic and non-diabetic donors identifies candidate genes that influence insulin secretion.Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analogMultimodal image coregistration and inducible selective cell ablation to evaluate imaging ligandsSynthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.Multimodality imaging of β-cells in mouse models of type 1 and 2 diabetesPharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis.Diabetes imaging-quantitative assessment of islets of Langerhans distribution in murine pancreas using extended-focus optical coherence microscopyImaging metabolic syndrome.A Novel Potential Positron Emission Tomography Imaging Agent for Vesicular Monoamine Transporter Type 2Pancreatic magnetic resonance imaging after manganese injection distinguishes type 2 diabetic and normoglycemic patients.Radioiodinated naphthylalanine derivatives targeting pancreatic beta cells in normal and nonobese diabetic mice.Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.Vesicular monoamine transporter, type 2 (VMAT2) expression as it compares to insulin and pancreatic polypeptide in the head, body and tail of the human pancreas.Imaging of beta-cell mass and functionThe utility of [(11)C] dihydrotetrabenazine positron emission tomography scanning in assessing beta-cell performance after sleeve gastrectomy and duodenal-jejunal bypassAmerican College of Endocrinology Pre-Diabetes Consensus Conference: part threeLife and death of β cells in Type 1 diabetes: A comprehensive review.Pancreatic beta cell mass PET imaging and quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in rodent models of diabetes.In vivo imaging of endogenous pancreatic β-cell mass in healthy and type 1 diabetic subjects using 18F-fluoropropyl-dihydrotetrabenazine and PET.Real-time imaging of the pancreas during development of diabetes.Bioluminescence imaging in mouse models quantifies beta cell mass in the pancreas and after islet transplantation.PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and ( --)-cocaine.Advances in beta-cell imagingAdvances in molecular imaging of pancreatic beta cellsLocalization and expression of VMAT2 aross mammalian species: a translational guide for its visualization and targeting in health and disease.Evaluation of pancreatic VMAT2 binding with active and inactive enantiomers of 18F-FP-DTBZ in baboonsRegenerative medicine for diabetes mellitus.
P2860
Q24653211-D2C909B1-B5EC-4EA0-9B6B-0C5CA3FBD68DQ27026331-1784ECE0-8C70-41CE-B420-9581269AE6F3Q30364628-D3370317-33C3-40F9-960C-0EFF4988A1B9Q30415463-98175512-2190-4F82-8844-8FBFFB6E4F70Q30436863-928E7BBB-EC16-4C96-A15E-70FEB9B59A16Q30454821-EDE620A6-3835-4474-8942-E41B60450B2FQ30828947-CED8DDAE-CA88-44DA-8965-167BFCB5F660Q33480823-0E21CB82-D26D-4264-BC19-472DCD50D277Q34283950-B21C9C51-1C68-42D0-8F29-DC94534919B2Q34356000-6145E17A-C7EB-425E-84E3-B01B5864A3E4Q34823681-D8C7169E-16B2-43AC-A4D3-6A50E6D5691FQ34983969-99875B4B-2E03-4D63-A541-FE504DF1117BQ35112943-AABAD385-FF3A-4306-91C9-1B0AE2BB1D2DQ35149660-243B30D1-C36B-42E4-84EF-52C3B741AD7AQ35651214-CD742F1A-BC9F-49FD-A8DB-58F0D828A27CQ35794797-13BAFD8B-0272-4B83-948F-6DB524DC0578Q35796917-ECEDF2A1-FFC0-4ED0-8354-DB8E1123849AQ35867486-8512109B-D3FF-47EB-B300-07ADA5313D2FQ35895009-415011C0-7449-4110-A7F4-F900FAE032B7Q36019448-4C1BE8EC-071D-46F9-8598-8C3611B12AE2Q36039286-94A98895-B3AA-4C3C-A59C-E203007FDB9EQ36128614-AEB86C7F-FB28-4B60-9371-7A384084915EQ36235357-C4109C84-31CB-4EE5-87F2-0F60AB01782CQ36645596-144A0E58-60A0-49EE-B6C3-14BD4102B29AQ36665699-8A50DB76-5A72-4F71-A986-D3EBDABAE5B9Q36707357-A4BB8445-0D41-4F4C-902F-FAFED58706A2Q36749622-5015F7BD-E35F-4567-877E-209E09DF0FE6Q36749627-D01CDC67-AB98-4E65-A111-BFFE553F9FB5Q36975760-9C145EB0-47BB-441C-A31F-28FB56B1C691Q36995568-5BB6A243-482A-401F-ACBB-C0D2125815B9Q37013071-434C3DC5-B5FA-4D59-9355-244C06C16952Q37080859-893DA8CD-B4D4-4607-90EC-623BC57FDC63Q37084899-FB1641AE-7069-418A-8275-1D0AC7BE48E0Q37292437-15020E19-21C6-4D9D-BCEA-C8BE16856E62Q37319768-9C5DC82D-9714-4FCF-957E-6195D49C9780Q37406437-74AAE2B3-5739-4E66-9617-AC70F40E5701Q37466693-C4D9BB0B-D7A1-4871-A9A7-7C635F5F23ADQ37591449-37F2519B-2FD5-4B27-8E30-7FB88B3AECCBQ37596164-CB945365-321D-42CE-A3E1-DDF158CCD3C8Q37602279-BABA5F33-7995-4159-8A3B-E3483B8FA7E2
P2860
Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@ast
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@en
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@nl
type
label
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@ast
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@en
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@nl
prefLabel
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@ast
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@en
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@nl
P2093
P2860
P356
P1476
Longitudinal noninvasive PET-b ...... pontaneous diabetes rat model.
@en
P2093
Anthony Raffo
Antonella Maffei
Chitra Saxena
Fabiola Souza
J John Mann
Mark Hardy
Michael Kilbourn
Norman Simpson
Paul E Harris
Ronald Van Heertum
P2860
P304
P356
10.1172/JCI27645
P407
P50
P577
2006-05-18T00:00:00Z